COMP <GO>
EDSA vs ALDX // OPERATING MARGIN
Edesa Biotech Inc. (NASDAQ) VS. Aldeyra Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EDSA 0
— ALDX 3
■ METRIC PARITY
LAST: $2.44 (-5.06%) • MKT CAP: $32.9M
operating-margins
—
LAST: $0.58 (+4.09%) • MKT CAP: $35.2M
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EDSA VS. ALDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EDSA | ALDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.08% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 4/9 | -3.00 | ALDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.4 | 32.6 | -0.20 | ALDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $32.9M | $35.2M | -$2.2M | ALDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EDSA REV | ALDX REV | EDSA GROSS % | ALDX GROSS % | EDSA FCF | ALDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $22.2M | $98.7M | — | — | -$7.3M | -$33.3M |
| FY 2024 | $19.6M | $168.3M | — | — | -$4.9M | -$43.2M |
| FY 2023 | $25.8M | $119.8M | — | — | -$6.6M | -$30.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EDSA // BETA —
ALDX // BETA —